SEC Form EFFECT filed by 8i Acquisition 2 Corp.
$LAX
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | September 21, 2023 4:00 P.M. |
| Form: | F-1 | ||||||
| |||||||
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | September 21, 2023 4:00 P.M. |
| Form: | F-1 | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
Singapore, Nov. 23, 2022 (GLOBE NEWSWIRE) -- 8i Acquisition 2 Corp. (the "Company" or "LAX") (NASDAQ:LAX), a publicly traded special purpose acquisition company, today announced the completion of its business combination (the "Business Combination") with EUDA Health Ltd ("EUDA Health"), a Singapore-based digital health platform that aims to make healthcare more affordable, accessible, and improve the patient experience by delivering improved outcomes through personalized healthcare. The combined company will operate under the name "EUDA Health Holdings Limited" (NASDAQ:EUDA) and will be led by Founder and Chief Executive Officer Dr. Kelvin Chen. Commencing at the open of trading on N
Singapore, Nov. 17, 2022 (GLOBE NEWSWIRE) -- 8i Acquisition 2 Corp. (the "Company" or "LAX") (NASDAQ:LAX), a publicly traded special purpose acquisition company, today announced the completion of its business combination (the "Business Combination") with EUDA Health Limited ("EUDA Health"), a Singapore-based digital health platform that aims to make healthcare more affordable, accessible, and improve the patient experience by delivering improved outcomes through personalized healthcare. The combined company will operate under the name "EUDA Health Holdings Limited" and will be led by Founder and Chief Executive Officer Dr. Kelvin Chen. Commencing at the open of trading on November 18, 202
Singapore, Nov. 10, 2022 (GLOBE NEWSWIRE) -- 8i Acquisition 2 Corp. (NASDAQ:LAX, the "Company"))), a special purpose acquisition company, announced today that all proposals presented to shareholders at the special meeting of shareholders held on November 10, 2022 at 10:00 a.m. Eastern Time relating to the Company's business combination with EUDA Health Limited were approved by shareholders. Holders of Company's ordinary shares that elected to redeem shares in connection with the Company's special meeting of shareholders may withdraw such redemption requests by no later than 5:00 p.m. Eastern Time on November 11, 2022. Based on a total of 8,195,770 ordinary shares tendered for redemption in
6-K - EUDA Health Holdings Ltd (0001847846) (Filer)
6-K - EUDA Health Holdings Ltd (0001847846) (Filer)
6-K - EUDA Health Holdings Ltd (0001847846) (Filer)
4 - EUDA Health Holdings Ltd (0001847846) (Issuer)
3 - EUDA Health Holdings Ltd (0001847846) (Issuer)
4 - EUDA Health Holdings Ltd (0001847846) (Issuer)
SC 13D/A - EUDA Health Holdings Ltd (0001847846) (Subject)
SC 13G/A - EUDA Health Holdings Ltd (0001847846) (Subject)
SC 13G/A - EUDA Health Holdings Ltd (0001847846) (Subject)